NASDAQ: NAMSNewamsterdam Pharma Co Nv Stock
$19.44-0.61 (-3.04%)
Updated Apr 18, 2024
NAMS Price
$19.44
Fair Value Price
$4.71
Market Cap
$1.74B
52 Week Low
$5.63
52 Week High
$26.35
P/E
-8.32x
P/B
5.54x
P/S
69.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.32M
Earnings
-$196.60M
Gross Margin
100%
Operating Margin
-1,255.57%
Profit Margin
-1,255.8%
Debt to Equity
0.2
Operating Cash Flow
-$157M
Beta
0.2
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NAMS Overview
Frazier Lifesciences Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets the biotechnology sector. Frazier Lifesciences Acquisition was incorporated in 2020 and is based in Seattle, WA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NAMS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NAMS ($19.44) is overvalued by 313.14% relative to our estimate of its Fair Value price of $4.71 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NAMS ($19.44) is not significantly undervalued (313.14%) relative to our estimate of its Fair Value price of $4.71 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NAMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NAMS due diligence checks available for Premium users.
Be the first to know about important NAMS news, forecast changes, insider trades & much more!
NAMS News
Valuation
NAMS fair value
Fair Value of NAMS stock based on Discounted Cash Flow (DCF)
Price
$19.44
Fair Value
$4.71
Overvalued by
313.14%
NAMS ($19.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NAMS ($19.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NAMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NAMS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-8.32x
Industry
15.68x
Market
41.33x
NAMS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.54x
Industry
5.76x
NAMS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NAMS's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
NAMS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NAMS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$385.7M
Liabilities
$65.2M
Debt to equity
0.2
NAMS's short-term assets ($376.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NAMS's short-term assets ($376.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NAMS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NAMS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NAMS vs Biotech Stocks
Newamsterdam Pharma Co Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.